Valeant Pharmaceuticals International Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 295 Posts
1 2 3 ... 19
2,800 Tuesday And The S&P – Are We There Yet?
Article By: Phil Davis Tuesday, July 10, 2018 10:05 AM EDT
66.6 Thousand. That's the volume the S&P's (SPY) ETF hasn't broken since June.
In this article: VRX, OILB, NDX, SPX, NYA, SPY, DJI
Read
Mizuho Says Synthetic Biologics IBS Treatment May Be 'Interesting' For Valeant
Article By: The Fly Friday, June 29, 2018 3:13 PM EDT
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals.
In this article: VRX, SYN
Read
Valeant Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly Wednesday, June 6, 2018 8:54 AM EDT
Barclays analyst Douglas Tsao upgraded Valeant Pharmaceuticals to Overweight from Equal Weight and raised his price target for the shares to $29 from $20.
In this article: VRX
Read
Key FDA Events In June Investors Need To Watch Out For
Article By: Zacks Investment Research Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
In this article: MRK, VRX, ARRY, GWPH, ALKS, AKAO
Read
Deutsche Raises Valeant Price Target On Extended Xifaxan Exclusivity
Article By: The Fly Monday, April 30, 2018 3:42 PM EDT
The stay in the Xifaxan litigation between Valeant Pharmaceuticals and Teva was recently extended to July 30, 2018, from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note.
In this article: VRX, TEVA
Read
Valeant Move Higher Amid Debt Offering, Insider Buying
Article By: The Fly Wednesday, March 14, 2018 5:30 PM EDT
Shares of specialty pharmacy company Valeant are higher this afternoon amid a relatively weak market backdrop.
In this article: VRX
Read
Deutsche Bank Says Buy Valeant After 'Significant Change' Over Last Two Years
Article By: The Fly Monday, March 5, 2018 12:41 PM EDT
Shares of Valeant Pharmaceuticals are on the rise after Deutsche Bank analyst Gregg Gilbert upgraded the stock to Buy.
In this article: VRX
Read
Piper Calls Valeant Management 'Overly Rosy,' Cuts Price Target To $10
Article By: The Fly Thursday, March 1, 2018 9:45 AM EDT
Management of Valeant Pharmaceuticals is taking an "overly rosy" long-term view of the business, Piper Jaffray analyst David Amsellem tells investors in a research note following the company's Q4 results.
In this article: VRX
Read
Can Valeant Bulls Stomach Double-Digit Revenue Declines?
Article By: Shock Exchange Monday, February 26, 2018 7:17 AM EDT
Can VRX bulls stomach double-digit revenue declines? Asset sales have helped pare debt and reduce corporate overhead. Asset sales could be halted for the moment. If LOE exceeds revenue from new products then VRX's credit metrics could deteriorate.
In this article: VRX Also: PSHZF
Read
Valeant: Generic Syprine Is Here
Article By: Shock Exchange Sunday, February 18, 2018 1:37 PM EDT
Teva announced the launch of generic Syprine, which treats Wilson's disease. Valeant's Syprine and Cuprimine have combined quarterly revenue and of $38MM. Hits to Syprine and Cuprimine could hurt sentiment for Valeant.
In this article: VRX, TEVA
Read
Valeant, Ackman Settle Insider Trading Lawsuit For $290 Million
Article By: Shock Exchange Wednesday, January 3, 2018 7:25 AM EDT
Valeant and Pershing Square settled their AGN insider trading case for $290MM. The settlement saved substantial time and resources. I believe there is a potential for future AGN shareholders to sue, creating a need for more settlements.
In this article: VRX, PSHZF, AGN
Read
Valeant Slips After JPMorgan Says Sell On Stretched Valuation, High Expectations
Article By: The Fly Thursday, December 14, 2017 4:16 PM EDT
Shares of Valeant Pharmaceuticals are sliding after JPMorgan analyst Chris Schott downgraded the stock to Underweight.
In this article: VRX
Read
Hot Options Report For End Of Day - Wednesday, November 22
Article By: The Options Insider Wednesday, November 22, 2017 5:37 PM EDT
Top tickers for end of day November 22: AAPL, VRX, GG, ILG, CBS and VALE.
In this article: AAPL, VRX, GG, ILG, CBS, VALE
Read
Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover
Article By: ChinaBio® Today Saturday, November 11, 2017 4:17 PM EDT
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products company, because US regulators refused to approve the deal, worried a China corporation would have access to US donor information.
In this article: VRX, CBMG
Read
Investors Pummel Celgene
Article By: Shock Exchange Friday, October 27, 2017 8:39 PM EDT
CELG fell over 15% after Q3 earnings Thursday. Weak guidance, slowing growth from Revlimid and questions over the pipeline spooked investors.
In this article: CELG, VRX, JNJ
Read
Concern Over Valeant's Financial Controls 'Likely Just Noise,' Says Cantor
Article By: The Fly Friday, October 13, 2017 8:17 PM EDT
Cantor Fitzgerald analyst Louise Chen says after speaking with the company, she believes the concerns are "likely just noise and cannot be strung together into an argument" that Valeant has issues with financial controls.
In this article: VRX Also: DEPO
Read
1 to 16 of 295 Posts
1 2 3 ... 19